Recursion Pharmaceuticals (RXRX) Non-Current Assets (2020 - 2026)

Recursion Pharmaceuticals' Non-Current Assets history runs 7 years deep, the most recent figure standing at $630.0 million for Q1 2026.

• Quarterly Non-Current Assets fell 12.64% year-over-year to $630.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 37.25% YoY) and the FY2025 annual result came in at $661.3 million, down 9.95% from the prior year.
• Non-Current Assets was $630.0 million for Q1 2026 at Recursion Pharmaceuticals, down from $661.3 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $734.3 million in Q4 2024 and bottomed at $114.9 million in Q1 2022.
• A 5-year average of $363.3 million and a median of $235.7 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2024 — Non-Current Assets jumped 240.66% — and 2026, when it retreated 12.64%.
• Recursion Pharmaceuticals' Non-Current Assets stood at $131.5 million in 2022, then soared by 63.96% to $215.6 million in 2023, then soared by 240.66% to $734.3 million in 2024, then declined by 9.95% to $661.3 million in 2025, then retreated by 4.74% to $630.0 million in 2026.
• Business Quant data shows RXRX's Non-Current Assets at $630.0 million in Q1 2026, $661.3 million in Q4 2025, and $685.4 million in Q3 2025.